Katherine Stueland Sells 51,420 Shares of GeneDx Holdings Corp. (NASDAQ:WGS) Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland sold 51,420 shares of GeneDx stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $94.48, for a total transaction of $4,858,161.60. Following the sale, the chief executive officer now directly owns 1,720 shares of the company’s stock, valued at approximately $162,505.60. This trade represents a 96.76 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Katherine Stueland also recently made the following trade(s):

• On Thursday, January 2nd, Katherine Stueland sold 18,006 shares of GeneDx stock. The shares were sold at an average price of $78.18, for a total value of $1,407,709.08.
• On Monday, December 16th, Katherine Stueland sold 10,501 shares of GeneDx stock. The stock was sold at an average price of $76.75, for a total value of $805,951.75.
• On Monday, December 9th, Katherine Stueland sold 3,661 shares of GeneDx stock. The shares were sold at an average price of $76.37, for a total value of $279,590.57.
• On Monday, November 18th, Katherine Stueland sold 22,307 shares of GeneDx stock. The stock was sold at an average price of $70.34, for a total value of $1,569,074.38.
• On Friday, November 15th, Katherine Stueland sold 23,108 shares of GeneDx stock. The stock was sold at an average price of $70.48, for a total transaction of $1,628,651.84.
• On Tuesday, October 29th, Katherine Stueland sold 2,154 shares of GeneDx stock. The shares were sold at an average price of $66.60, for a total transaction of $143,456.40.

GeneDx Stock Performance

Shares of WGS stock opened at $89.38 on Friday. GeneDx Holdings Corp. has a 52-week low of $2.85 and a 52-week high of $98.87. The stock’s 50-day moving average price is $78.01 and its 200 day moving average price is $53.19. The company has a quick ratio of 2.27, a current ratio of 2.40 and a debt-to-equity ratio of 0.25. The stock has a market capitalization of $2.46 billion, a PE ratio of -28.74 and a beta of 2.02.

GeneDx (NASDAQ:WGS) last released its earnings results on Tuesday, October 29th. The company reported $0.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.25. GeneDx had a negative return on equity of 13.35% and a negative net margin of 31.25%. The business had revenue of $76.90 million for the quarter, compared to analyst estimates of $64.98 million. During the same quarter in the previous year, the company posted ($0.82) earnings per share. The company’s revenue for the quarter was up 44.3% compared to the same quarter last year. As a group, equities research analysts forecast that GeneDx Holdings Corp. will post -0.24 EPS for the current year.

Institutional Trading of GeneDx

Several hedge funds have recently made changes to their positions in WGS. Acadian Asset Management LLC acquired a new position in shares of GeneDx during the second quarter worth about $34,000. CWM LLC purchased a new stake in GeneDx in the 3rd quarter valued at approximately $89,000. SG Americas Securities LLC acquired a new position in GeneDx during the 3rd quarter worth approximately $198,000. Point72 DIFC Ltd purchased a new position in shares of GeneDx during the 3rd quarter worth approximately $220,000. Finally, Palumbo Wealth Management LLC acquired a new stake in shares of GeneDx in the 3rd quarter valued at approximately $287,000. Institutional investors and hedge funds own 61.72% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have issued reports on the stock. Craig Hallum upped their price objective on shares of GeneDx from $70.00 to $95.00 and gave the company a “buy” rating in a research note on Wednesday, October 30th. The Goldman Sachs Group raised their price target on GeneDx from $54.00 to $70.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 30th. TD Cowen lifted their price target on GeneDx from $75.00 to $118.00 and gave the stock a “buy” rating in a research report on Tuesday. Finally, Wells Fargo & Company increased their price objective on GeneDx from $34.00 to $75.00 and gave the company an “equal weight” rating in a report on Wednesday, October 30th. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $70.67.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.